Friday, July 10, 2026

pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell

Samsung Bioepis

Samsung Bioepis is a pharma organization headquartered in KR. Primary therapeutic focus areas include Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach, Dyspepsia, Depression. NovaPharmaNews links 24 c

Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
Status
Public
HQ
Yeonsu-gu, Incheon 21987, KR
Founded
2012
Employees
1,589
Programs
24
Drugs
34
Patents
0
Clinical program

POHIM-RT

Unknown · other · Cervix Cancer

POHIM-RT for Cervix Cancer is a Unknown program (other) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).

Internal code SMC 2017-03-092-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Samsung Bioepis NL B.V.
Phase
Unknown
Modality
other
Indication
Cervix Cancer
Status
active
Trials
1

Clinical trials